Archive · 20 Nov 2025
Marksans Pharma Expands Allergy Treatment Portfolio with UK Approval
Marksans Pharma's UK branch got permission to sell a new medicine for allergies in the UK.
This medicine is used to treat different types of allergies.
The company's stock price went up after this news.
Recently, the company has also received approvals for other medicines in the UK and the US.
Marksans Pharma's UK subsidiary, Relonchem Limited, received marketing authorisation from the MHRA for Cetirizine Dihydrochloride 1 mg/ml oral solution
The anti-allergy medicine is used to relieve seasonal and year-round allergies, including hay fever and hives
This approval expands the company's allergy treatment portfolio
Marksans Pharma's shares closed ₹3.87 higher at ₹193.02 following the announcement
The company has recently secured several regulatory wins, including a US FDA approval for an anti-diarrhoeal medicine
- Who
- Marksans Pharma's UK subsidiary, Relonchem Limited
- What
- Received marketing authorisation for Cetirizine Dihydrochloride 1 mg/ml oral solution
- When
- On Thursday
- Where
- In the UK
- Why
- To expand its allergy treatment portfolio
- Medicine
- Cetirizine Dihydrochloride 1 mg/ml oral solution
- Use
- Relieves seasonal and year-round allergies, including hay fever and hives
- Stock Price Change
- Up ₹3.87 to ₹193.02
- Recent Approvals
- US FDA approval for Loperamide Hydrochloride Tablets USP, 2 mg and MHRA approval for Mefenamic Acid film-coated tablets